Howes O, Bukala B, Beck K
Nat Rev Neurol. 2023; 20(1):22-35.
PMID: 38110704
DOI: 10.1038/s41582-023-00904-0.
McCutcheon R, Krystal J, Howes O
World Psychiatry. 2020; 19(1):15-33.
PMID: 31922684
PMC: 6953551.
DOI: 10.1002/wps.20693.
Russo M, Carrarini C, Dono F, Rispoli M, Di Pietro M, Di Stefano V
Front Pharmacol. 2020; 10:1379.
PMID: 31920635
PMC: 6913661.
DOI: 10.3389/fphar.2019.01379.
Amato D, Kruyer A, Samaha A, Heinz A
Front Psychiatry. 2019; 10:314.
PMID: 31214054
PMC: 6557273.
DOI: 10.3389/fpsyt.2019.00314.
Auffret M, Drapier S, Verin M
Drugs R D. 2018; 18(2):91-107.
PMID: 29546602
PMC: 5995787.
DOI: 10.1007/s40268-018-0230-3.
Regulation of dopaminergic function: an [F]-DOPA PET apomorphine challenge study in humans.
Jauhar S, Veronese M, Rogdaki M, Bloomfield M, Natesan S, Turkheimer F
Transl Psychiatry. 2017; 7(2):e1027.
PMID: 28170002
PMC: 5438020.
DOI: 10.1038/tp.2016.270.
Dopamine receptor signaling and current and future antipsychotic drugs.
Boyd K, Mailman R
Handb Exp Pharmacol. 2012; (212):53-86.
PMID: 23129328
PMC: 4711768.
DOI: 10.1007/978-3-642-25761-2_3.
The nature of dopamine dysfunction in schizophrenia and what this means for treatment.
Howes O, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A
Arch Gen Psychiatry. 2012; 69(8):776-86.
PMID: 22474070
PMC: 3730746.
DOI: 10.1001/archgenpsychiatry.2012.169.
Treatment mechanisms: traditional and new antipsychotic drugs.
Tamminga C
Dialogues Clin Neurosci. 2011; 2(3):281-6.
PMID: 22033640
PMC: 3181604.
Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?.
Mailman R, Murthy V
Curr Pharm Des. 2009; 16(5):488-501.
PMID: 19909227
PMC: 2958217.
DOI: 10.2174/138161210790361461.
Induction of tolerance of dopaminergic responses in man.
Lal S, Thavundayil J, Ng Ying Kin N, Dai X, Schwartz G, Montoya A
J Neural Transm (Vienna). 2008; 115(8):1189-98.
PMID: 18506387
DOI: 10.1007/s00702-008-0068-x.
GPCR functional selectivity has therapeutic impact.
Mailman R
Trends Pharmacol Sci. 2007; 28(8):390-6.
PMID: 17629962
PMC: 2958218.
DOI: 10.1016/j.tips.2007.06.002.
Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder.
Mostafavi Abdolmaleky H, Cheng K, Faraone S, Wilcox M, Glatt S, Gao F
Hum Mol Genet. 2006; 15(21):3132-45.
PMID: 16984965
PMC: 2799943.
DOI: 10.1093/hmg/ddl253.
Stimulation of D2 receptors in the prefrontal cortex reduces PCP-induced hyperactivity, acetylcholine release and dopamine metabolism in the nucleus accumbens.
Del Arco A, Mora F, Mohammed A, Fuxe K
J Neural Transm (Vienna). 2006; 114(2):185-93.
PMID: 16897609
DOI: 10.1007/s00702-006-0533-3.
Altered prepulse inhibition in rats treated prenatally with the antimitotic Ara-C: an animal model for sensorimotor gating deficits in schizophrenia.
Elmer G, Sydnor J, Guard H, Hercher E, Vogel M
Psychopharmacology (Berl). 2004; 174(2):177-89.
PMID: 14985933
DOI: 10.1007/s00213-003-1757-7.
Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?.
Depatie L, Lal S
J Psychiatry Neurosci. 2001; 26(3):203-20.
PMID: 11394190
PMC: 1408306.
Local and distributed effects of apomorphine on fronto-temporal function in acute unmedicated schizophrenia.
Fletcher P, Frith C, Grasby P, Friston K, Dolan R
J Neurosci. 1996; 16(21):7055-62.
PMID: 8824341
PMC: 6579275.
Dopamine agonists facilitate footshock-elicited locomotion in rats, and suppress level-press responding for food.
Franklin S, Tang A
Psychopharmacology (Berl). 1995; 121(4):480-4.
PMID: 8619012
DOI: 10.1007/BF02246497.
Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia.
Grace A
J Neural Transm Gen Sect. 1993; 91(2-3):111-34.
PMID: 8099795
DOI: 10.1007/BF01245228.
Differential effects of 3-PPP enantiomers on extracellular dopamine concentration in the caudate-putamen and nucleus accumbens of rats.
See R
Naunyn Schmiedebergs Arch Pharmacol. 1994; 350(6):605-10.
PMID: 7708117
DOI: 10.1007/BF00169364.
